Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation
暂无分享,去创建一个
[1] M. King,et al. Response to DNA damage of CHEK2 missense mutations in familial breast cancer. , 2012, Human molecular genetics.
[2] M. Olivier,et al. Sarcomas in TP53 germline mutation carriers , 2012, Cancer.
[3] J. Bartek,et al. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations , 2011, Breast Cancer Research and Treatment.
[4] S. Pai,et al. p53+/mdm2− Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma in Young Children: An Early Expression of Li-Fraumeni Syndrome , 2010, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[5] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[6] M. Garrett,et al. CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin? , 2007, Nature Reviews Cancer.
[7] T. Walsh,et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.
[8] R. Eeles,et al. Increasing evidence that germline mutations in CHEK2 do not cause Li‐Fraumeni syndrome , 2002, Human mutation.
[9] T. Halazonetis,et al. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.
[10] K. Isselbacher,et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.
[11] F. Rilke,et al. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4‐containing amplicons at 12q13–22 , 1998, The Journal of pathology.
[12] F. Rilke,et al. DISTINCT mdm2/p53 EXPRESSION PATTERNS IN LIPOSARCOMA SUBGROUPS: IMPLICATIONS FOR DIFFERENT PATHOGENETIC MECHANISMS , 1997, The Journal of pathology.
[13] P. Cin,et al. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. , 1993, Cancer genetics and cytogenetics.
[14] H. Lynch,et al. Genetic and pathologic findings in a kindred with hereditary sarcoma breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma , 1978, Cancer.
[15] R. Schneider-Stock,et al. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas , 1998, Journal of Cancer Research and Clinical Oncology.
[16] R. Schneider-Stock,et al. On telomere shortening in soft-tissue tumors , 1998, Journal of Cancer Research and Clinical Oncology.